H Kovar
Overview
Explore the profile of H Kovar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katschnig A, Kauer M, Schwentner R, Tomazou E, Mutz C, Linder M, et al.
Oncogene
. 2017 Jul;
36(43):5995-6005.
PMID: 28671673
Ewing sarcoma (EWS) is a paediatric bone cancer with high metastatic potential. Cellular plasticity resulting from dynamic cytoskeletal reorganization, typically regulated via the Rho pathway, is a prerequisite for metastasis...
2.
Ruiz-Pinto S, Pita G, Patino-Garcia A, Garcia-Miguel P, Alonso J, Perez-Martinez A, et al.
Ann Oncol
. 2016 Jun;
27(9):1788-93.
PMID: 27287205
Background: Despite the effectiveness of current treatment protocols for Ewing sarcoma (ES), many patients still experience relapse, and survival following recurrence is <15%. We aimed to identify genetic variants that...
3.
VENTURA S, Aryee D, Felicetti F, De Feo A, Mancarella C, Manara M, et al.
Oncogene
. 2015 Dec;
35(30):3944-54.
PMID: 26616853
Sarcomas are mesenchymal tumors characterized by blocked differentiation process. In Ewing sarcoma (EWS) both CD99 and EWS-FLI1 concur to oncogenesis and inhibition of differentiation. Here, we demonstrate that uncoupling CD99...
4.
Bolling T, Braun-Munzinger G, Burdach S, Calaminus G, Craft A, Delattre O, et al.
Klin Padiatr
. 2015 May;
227(3):108-15.
PMID: 25985445
Curative therapies for Ewing sarcoma have been developed within cooperative groups. Consecutive clinical trials have systematically assessed the impact and timing of local therapy and the activity of cytotoxic drugs...
5.
Aryee D, Niedan S, Ban J, Schwentner R, Muehlbacher K, Kauer M, et al.
Br J Cancer
. 2013 Oct;
109(10):2696-704.
PMID: 24129240
Background: Though p53 mutations are rare in ES, there is a strong indication that p53 mutant tumours form a particularly bad prognostic group. As such, novel treatment strategies are warranted...
6.
Niedan S, Kauer M, Aryee D, Kofler R, Schwentner R, Meier A, et al.
Oncogene
. 2013 Sep;
33(30):3927-38.
PMID: 23995784
The Ewing sarcoma (ES) EWS-FLI1 chimeric oncoprotein is a prototypic aberrant ETS transcription factor with activating and repressive regulatory functions. We report that EWS-FLI1-repressed promoters are enriched in forkhead box...
7.
Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee D, et al.
Oncogene
. 2011 Jan;
30(18):2173-80.
PMID: 21217773
EWS-FLI1 is a chromosome translocation-derived chimeric transcription factor that has a central and rate-limiting role in the pathogenesis of Ewing's sarcoma. Although the EWS-FLI1 transcriptomic signature has been extensively characterized...
8.
Scotlandi K, Picci P, Kovar H
Curr Cancer Drug Targets
. 2009 Dec;
9(7):843-53.
PMID: 20025572
The treatment of sarcoma urgently requires new, innovative therapeutic strategies. The most recent improvements in the cure of patients with localized disease have been achieved by dose-intensification, in turn paying...
9.
Bachmaier R, Aryee D, Jug G, Kauer M, Kreppel M, Lee K, et al.
Oncogene
. 2009 Jan;
28(9):1280-4.
PMID: 19151750
The oncogene EWS-FLI1 encodes a chimeric transcription factor expressed in Ewing's sarcoma family tumors (ESFTs). EWS-FLI1 target gene expression is thought to drive ESFT pathogenesis and, therefore, inhibition of EWS-FLI1...
10.
Kovar H
Sarcoma
. 2008 Jun;
2(1):3-17.
PMID: 18521227
Purpose/results/discussion. Rearrangement of the EWS gene with an ETS oncogene by chromosomal translocation is a hallmark of the Ewing family of tumors (EFT). Detectability, incidence, tumor specificity and variability of...